GlassScriptPhysician profile
Maria Bartkus
NPI 1780246736
$3,108.20
in general payments reported to CMS, 2019-2025
34 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $515 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $431.52 | 2025 | |
| Sk Life Science, INC. | $336.56 | 2024-2025 | Xcopri |
| Tg Therapeutics, INC. | $308.49 | 2024-2025 | |
| Abbvie INC. | $233.87 | 2024-2025 | |
| Lundbeck LLC | $188.42 | 2024-2025 | Vyepti |
| Eisai INC. | $174.63 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $129.14 | 2024-2025 | Ultomiris |
| Biogen, INC. | $115.85 | 2024-2025 | Tysabri, Vumerity, Leqembi |
| Mdd US Operations, LLC | $115.71 | 2025 | |
| Ucb, INC. | $107.26 | 2024-2025 | Rystiggo, Zilbrysq, Briviact |
| Genentech USA, INC. | $98.63 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Argenx US, INC. | $85.33 | 2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $70.05 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $69.72 | 2025 | Wainua |
| Kedrion Biopharma, INC. | $62.86 | 2024-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $55.45 | 2024-2025 | Dysport |
| Amgen INC. | $50.18 | 2025 | Uplizna |
| Csl Behring | $49.63 | 2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $45.63 | 2024-2025 | Ponvory |
| Alnylam Pharmaceuticals INC. | $44.78 | 2025 | Onpattro |
| Catalyst Pharmaceuticals, INC. | $39.29 | 2024-2025 | |
| Tanabe Pharma America, INC. | $35.54 | 2025 | Radicava |
| Pfizer INC. | $32.34 | 2025 | |
| Neuropace, INC. | $26.75 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.97 | 2025 | Rexulti |
| Invivyd INC | $24.19 | 2025 | Pemgarda |
| Mallinckrodt Hospital Products INC. | $23.43 | 2025 | Acthar |
| Lilly USA, LLC | $23.05 | 2025 | Kisunla |
| Grifols USA, LLC | $22.08 | 2025 | Gamunex-C |
| Life Molecular Imaging LTD | $20.59 | 2024 | Neuraceq |
| Ani Pharmaceuticals, INC. | $19.04 | 2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $14.74 | 2025 | Austedo Xr |
| Neurelis, INC. | $14.29 | 2024 | Valtoco |
| Cycle Pharmaceuticals INC | $14.19 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Bartkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.